阿帕替尼治疗晚期肺癌对患者血清肿瘤标志物的影响研究

Effect of apatinib on serum tumor markers in patients with advanced lung cancer

目的:探讨阿帕替尼对晚期肺癌患者血清肿瘤标志物癌胚抗原(CEA)、糖抗原125(CA 125)、神经元特异性烯醇化酶(NSE)、鳞状细胞癌抗原(SCC)、细胞角蛋白19片段(CyFRA21-1)的影响。方法:选择82例初诊并确诊为肺癌晚期患者作为研究组,选择同期75例肺部良性疾病的患者作为肺疾病良性组,同期80例健康的体检者作为健康组。测定其值采用相对应的试剂盒及全自动化学发光免疫分析仪,比较并分析阿帕替尼治疗前后对血清肿瘤标志物的影响及临床应用价值。结果:肺癌组各肿瘤标志物均显著高于健康组、肺疾病良性组,比较差异有统计学意义(P<0.05);在不同的治疗时间段,患者血清肿瘤标志物均有降低,在治疗4个月后,与健康组相比,肺癌患者血清的CEA、CA 125、SCC值差异无统计学意义,但与肺癌组比较差异有统计学意义(P<0.05);5种血清肿瘤标志物联合后,敏感度显著高于单一检测的肿瘤标志物(P<0.05);阿帕替尼治疗肺癌患者结束后,ORR(客观缓解率)达到17.07%,DCR(疾病控制率)达到53.66%,总生存时间(OS)超过6个月。结论:阿帕替尼可有效的缓解肺癌患者血清肿瘤标志物,为治疗肺癌晚期患者提供了一定的临床依据。

Objective:To investigate the effect of apatinib on serum tumor markers carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA 125),neuron specific enolase(NSE),squamous cell carcinoma antigen(SCC)and cytokeratin 19 fragment(CYFRA21-1)in patients with advanced lung cancer.Methods:82 patients with advanced lung cancer were selected as research group,and 75 patients with benign lung disease were selected as benign group,and 80 healthy people were selected as healthy group.The corresponding kits and full-automatic chemiluminescence immunoassay instrument were used to compare and analyze the effect of apatinib on serum tumor markers before and after treatment and its clinical application value.Results:The tumor markers in research group were significantly higher than those in healthy group and benign group(P<0.05).In different treatment periods,serum tumor markers of patients were decreased.After 4 months of treatment,there was significant difference in serum CEA,CA 125,SCC between research group and healthy group.After combination of five serum tumor markers,the sensitivity was significantly higher than that of single detection tumor marker(P<0.05).After the end of apatinib treatment of lung cancer patients,objective remission rate(ORR)reached 17.07%,disease control rate(DCR)reached 53.66%,and the overall survival time(OS)exceeded six months.Conclusion:Apatinib can effectively alleviate the serum tumor markers in patients with lung cancer,which provides a certain clinical basis for the treatment of patients with advanced lung cancer.